Polaryx Therapeutics (PLYX) Net Cash Flow (2025 - 2026)
Polaryx Therapeutics (PLYX) posted quarterly Net Cash Flow of -$2.1 million for Q1 2026, down 349.46% year-over-year from $827001.7 in Q1 2025, and down 349.46% quarter-over-quarter from -$459000.0 in Q1 2025.
Polaryx Therapeutics (PLYX) Net Cash Flow (2025 - 2026) Analysis & Trends
Polaryx Therapeutics (PLYX) has reported Net Cash Flow for 2 consecutive years, with -$2.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow fell 349.46% year-over-year to -$2.1 million; the TTM figure through Mar 2026 stood at -$2.5 million (changed N/A YoY), while the FY2025 annual figure was $522000.0, down 88.7% from the prior year.
- Net Cash Flow eased to -$2.1 million in Q1 2026 per PLYX's latest filing, from -$459000.0 in the prior quarter.
- Across five years, Net Cash Flow topped out at -$459000.0 in Q1 2025 and bottomed at -$2.1 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -496,000.00 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -37.14 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 225.59 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -2.83 Bn |
| 10 | Polaryx Therapeutics | 102.35 Mn | 90.81 Mn | - | -1.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.33 Mn |
| Jun 30, 2026 | -1.33 Mn |
| Mar 31, 2026 | -2.06 Mn |
| Mar 31, 2026 | -2.06 Mn |
| Mar 31, 2025 | -459,000.00 |
| Mar 31, 2025 | -459,000.00 |